Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 24.80 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 06:50PM GMT
Release Date Price: $35.46 (+0.60%)
Dae Gon Ha
Stifel, Nicolaus & Company, Incorporated, Research Division - Research Analyst

All right. Good afternoon, everyone. Thanks for joining the afternoon session. My name is Dave Ona. I'm one of the biotech analysts here. With me for this next 25, 30 minutes, we have Ultragenyx. And with me on stage, we have Founder President and CEO, Emil Kakkis. Dr. Emil Kakkis, we'll start off with a short intro of the company, a couple of slides accompanying it, and then we'll jump right into the question.Â

So with that, Emil, thank you.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Thanks for having me, Dave. I'm good to be here. So our forward-looking statement. As a company, we were formed in 2010. So this is completed 12 years. We're in the 2013, '14 IPO class. And we have a growing commercial revenue, we talk about now with 3 products, the fourth product we just acquired with high growth. Plus, we also have a strong clinical pipeline with 5 programs at Pivotal or post pivotal and combine that, we have not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot